Showing 41 - 48 results of 48 for search '"therapeutic drug monitoring"', query time: 0.06s Refine Results
  1. 41

    Plasma Concentrations of Benzylpenicillin and Cloxacillin in Infective Endocarditis—With Special Reference to Delayed Hypersensitivity Reactions by Malin Hägglund, Ulrika Snygg-Martin, Lars Olaison, Michael Stofkoper, Bert Ove Larsson, Magnus Brink

    Published 2025-01-01
    “…Dose adjustments guided by therapeutic drug monitoring (TDM) could mitigate these risks while maintaining treatment efficacy. …”
    Get full text
    Article
  2. 42

    Development and Application of a LC-MS/MS Method for Simultaneous Quantification of Four First-Line Antituberculosis Drugs in Human Serum by Yunliang Zheng, Nana Xu, Xingjiang Hu, Qiao Zhang, Yanpeng Liu, Qingwei Zhao

    Published 2020-01-01
    “…This method was successfully applied to the quantification of four first-line antituberculosis (anti-TB) drugs, suggesting its suitability for therapeutic drug monitoring in the clinical practices.…”
    Get full text
    Article
  3. 43

    Usefulness of a TDM-Guided Approach for Optimizing Teicoplanin Exposure in the Treatment of Secondary Bloodstream Infections Caused by Glycopeptide-Susceptible <i>Enterococcus faec... by Milo Gatti, Matteo Rinaldi, Maddalena Giannella, Pierluigi Viale, Federico Pea

    Published 2025-01-01
    “…To assess the clinical usefulness of teicoplanin optimized by means of a therapeutic drug monitoring (TDM)-guided approach for treating secondary bloodstream infections (BSIs) caused by <i>Enterococcus faecium</i>. …”
    Get full text
    Article
  4. 44

    Predicting the exposure of mycophenolic acid in children with autoimmune diseases using a limited sampling strategy: A retrospective study by Ping Zheng, Ting Pan, Ya Gao, Juan Chen, Liren Li, Yan Chen, Dandan Fang, Xuechun Li, Fei Gao, Yilei Li

    Published 2025-01-01
    “…Abstract Mycophenolic acid (MPA) is commonly used to treat autoimmune diseases in children, and therapeutic drug monitoring is recommended to ensure adequate drug exposure. …”
    Get full text
    Article
  5. 45

    Innovative MOF-enhanced electroanalytical approach for sensitive sunitinib malate detection in renal carcinoma patients using CuO/lanthanum MOF-modified carbon paste electrode by Azza H. Rageh, Mohamed I. Said, Asmaa Abdeltawab, Fatma A.M. Abdel-aal

    Published 2025-08-01
    “…Moreover, the proposed methodology via modification of CPE with the synthesized MOFs tailors them to be applied for clinical analysis and therapeutic drug monitoring of SUN, providing a valuable tool for personalized medicine and improving the treatment outcomes for renal cancer patients.…”
    Get full text
    Article
  6. 46

    Involvement of HLADQA1*05 in Patients with Inflammatory Bowel Disease Treated with Anti-TNF Drugs by Anna Pau, Ilaria Galliano, Elisa Barnini, Maddalena Dini, Antonio Pizzol, Alice Ponte, Stefano Gambarino, Pier Luigi Calvo, Massimiliano Bergallo

    Published 2025-01-01
    “…<i>Methods</i>: Sixty-five paediatric IBD patients were enrolled, with therapeutic drug monitoring (TDM) of IFX and ADA, conducted using immunoenzymatic assays. …”
    Get full text
    Article
  7. 47

    Tacrolimus- and Mycophenolate-Mediated Toxicity: Clinical Considerations and Options in Management of Post-Transplant Patients by Alan D. Kaye, Shivam S. Shah, Coplen D. Johnson, Adalyn S. De Witt, Austin S. Thomassen, Charles P. Daniel, Shahab Ahmadzadeh, Sridhar Tirumala, Kristin Nicole Bembenick, Adam M. Kaye, Sahar Shekoohi

    Published 2024-12-01
    “…Mycophenolate, a reversible inhibitor of inosine monophosphate dehydrogenase, frequently causes gastrointestinal disturbances, including diarrhea and colitis, as well as hematologic side effects like anemia and leukopenia, which increase infection risk. Therapeutic drug monitoring (TDM) and pharmacogenomics have emerged as essential strategies for mitigating these toxicities. …”
    Get full text
    Article
  8. 48

    Impact of donor CYP3A5 genotype on pharmacokinetics of tacrolimus in South African paediatric liver transplant patients by C Wheeler, C Masimirembwa, B Mthembu, J Botha, J Scholefield, J Fabian

    Published 2024-04-01
    “…It is characterised by a narrow therapeutic index and wide interpatient variability, necessitating therapeutic drug monitoring of whole-blood concentrations. Pharmacogenetic research, although not representative of SA population groups, suggests that single-nucleotide polymorphisms within the cytochrome P450 3A5 (CYP3A5) gene contribute to the variability in tacrolimus dosing requirements. …”
    Get full text
    Article